Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Elahere
Pharma
AbbVie's ImmunoGen buyout bears fruit with midstage trial win
AbbVie's newly acquired antibody-drug conjugate Elahere has met the mark in a midstage trial in certain ovarian cancer patients.
Fraiser Kansteiner
Jun 6, 2024 11:22am
In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen
Feb 12, 2024 10:55am
With $10B deal, AbbVie doubles down on red-hot ADC field
Nov 30, 2023 9:16am
ImmunoGen's ADC Elahere delivers landmark ovarian cancer win
May 3, 2023 3:23pm
ImmunoGen gains FDA nod for advanced ovarian cancer drug Elahere
Nov 15, 2022 11:03am
